Medicus pharma provides update on sknjct-003 phase 2 clinical study for the treatment of nodular basal cell carcinoma (bcc)

The company is on track to complete the interim data analysis before the end of q1 2025 and to submit the findings to the u.s. food and drug administration (fda) philadelphia, pennsylvania--(newsfile corp. - february 14, 2025) - medicus pharma ltd. (nasdaq: mdcx) ("medicus" or the "company") is also pleased to announce that its phase 2 clinical study (sknjct-003), which is currently underway in nine (9) clinical sites in united states, has now randomized more than 50% of the 60 patients expected to be enrolled in the study.
BCC Ratings Summary
BCC Quant Ranking